Sign In
Buy GCTK
$0.665
+0.0044 (+0.666%)
At Close: Jun 03, 2026
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commerc
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
05:27pm, Thursday, 14'th May 2026
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
01:00pm, Thursday, 07'th May 2026
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform Submission supports advancement of a long‑term, fully implantable, blood‑b
RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and comme
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and comme
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
04:50pm, Monday, 30'th Mar 2026
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Increases By 53.5%
03:17am, Monday, 30'th Mar 2026
GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 43,428 shares, an increase of 53.5%
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
08:01am, Friday, 27'th Mar 2026
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 Experience From Brazilian an
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
08:01am, Tuesday, 10'th Mar 2026
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercia
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
08:01am, Thursday, 29'th Jan 2026
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercial
GlucoTrack (NASDAQ:GCTK) Trading 2.9% Higher – Here’s What Happened
03:33am, Thursday, 22'nd Jan 2026
GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) shares traded up 2.9% during trading on Wednesday. The company traded as high as $4.20 and last traded at $3.91. 2,536,909 shares traded hands during
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel
GlucoTrack (NASDAQ:GCTK) Stock Price Down 2.2% – Here’s What Happened
03:46am, Wednesday, 24'th Dec 2025
Shares of GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) were down 2.2% on Tuesday. The stock traded as low as $4.45 and last traded at $4.50. Approximately 10,583 shares were traded during mid-day
GlucoTrack (NASDAQ:GCTK) Stock Price Down 7.5% – Here’s What Happened
02:52am, Tuesday, 02'nd Dec 2025
GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report)'s stock price dropped 7.5% on Monday. The company traded as low as $6.27 and last traded at $6.29. Approximately 9,069 shares changed hands during tra
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
04:05pm, Thursday, 13'th Nov 2025
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expe
